- Largest EUS-HGS study, 33% adverse events; median survival 144 days
- 19.1% had recurrent obstruction; stent efficacy declines over a year
- Partially covered stents & distal stenoses show better outcomes
https://t.co/NG4ico12df
@WileyHealth@my_ueg@joostphdrenth
Just in @NEJM : Thalidomide effective for bleeding due to small-intestinal angiodysplasia
✅Patients with portal hypertension probably included as only those with "esophageal varices & cirrhosis" were excluded. Not mentioned 🤔
⚠️ side effect 🟰 elevated liver-enzyme levels
Une première réalisée par les équipes de chirurgie digestive et oncologique du Pr Mehdi Karoui, d'HGE et endoscopie digestive du Pr Christophe Cellier et d'anesthésie réanimation du Pr Bernard Cholley @HopitalPompidou@APHP@CellierChristo5@GodierAnne
Inauguration de la salle hydride: CPRE et cholécystectomie en 1 temps/en 1 lieu pour un patient insuffisant cardiaque assisté d’un LVAD. Une première, réalisée grâce aux équipes d’endoscopie,de chirurgie digestive,de l’UMICS et d’anesthésie-réa (nous sommes très fiers!).@SFAR_ORG
ADDR in press: "Regenerative medicine for digestive fistulae therapy: benefits, challenges and promises of stem/stromal cells and emergent perspectives via their extracellular vesicles"
By Amanda K A Silva & coworkers @AmandaSilvaBru1 @Univ_Paris
https://t.co/AsAYGRtAfy
'The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor'
#ustekinumab#vedolizumab#Crohns#gastroenterology
Read FREE at https://t.co/41zK1zIRtZ
"ustekinumab... a higher rate of clinical remission"